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Abstract
Background & Aims: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable 
responses, manageable safety, and increased survival in patients with advanced hepatocellular 
carcinoma (HCC). In our retrospective analysis, we studied the immunobiology and potential 
associations between biomarkers and outcomes with nivolumab in HCC.
Methods: Fresh and archival tumour samples from dose-escalation and dose-expansion phases of 
the CheckMate 040 trial were analysed by immunohistochemistry and RNA sequencing to assess 
several inflammatory gene expression signatures, including CD274 (PD-ligand 1 [PD-L1]), 
CD8A, LAG3, and STAT1. Biomarkers were assessed for association with clinical outcomes (best 
overall response by blinded independent central review per RECIST v1.1 and overall survival 
[OS]).
Results: Complete or partial tumour responses were observed in PD-L1–positive and PD-L1–
negative patients treated with nivolumab monotherapy. Median OS was 28.1 (95% CI 18.2–n.a.) 
vs. 16.6 months (95% CI 14.2–20.2) for patients with tumour PD-L1 ≥1% vs. <1% (p = 0.03). 
Increased CD3 and CD8 showed a non-significant trend towards improved OS (both p = 0.08), and 
macrophage markers were not associated with OS. Tumour PD-1 and PD-L1 expression were 
associated with improved OS (p = 0.05 and p = 0.03, respectively). An inflammatory gene 
signature consisting of 4 genes was associated with improved objective response rate (p = 0.05) 
and OS (p = 0.01).
Conclusions: PD-1 and PD-L1 expression, biomarkers of inflammation, and inflammatory gene 
signatures trended with improved survival and response. While further confirmation within a 
larger phase III trial is needed to evaluate predictive value of these biomarkers, these exploratory 
analyses suggest that anti-tumour immune response may play a role in the treatment benefit of 
nivolumab in HCC.
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Lay summary: Certain tests may be used to provide a picture of how a tumour is escaping the 
immune system, allowing it to continue to grow and create more tumours. Therapies such as 
nivolumab are designed to help the immune system fight the tumour. These tests may be used to 
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Introduction
Recently, new therapies have emerged expanding the treatment landscape for patients with 
advanced hepatocellular carcinoma (HCC) who have progressed following first-line 
systemic therapy. These agents have been evaluated in multiple phase III, randomised, 
controlled trials with sorafenib-experienced patients and have shown improved median 
overall survival (OS) ranging from 8.5 to 10.6 months.1-3 While these results are 
encouraging, OS remains modest and resistance is common.4 Therefore, there is an unmet 
need for additional therapies, such as immune checkpoint inhibitors (ICIs), and for exploring 
biomarkers that can identify patients who may benefit the most from these treatments.
CheckMate 040 (NCT01658878) is a phase I/II, open-label, non-comparative, multicohort 
trial of nivolumab in adults (≥18 years) with histologically confirmed advanced HCC with or 
without chronic viral hepatitis (HCV or HBV).5 In the dose-escalation and dose-expansion 
cohorts, nivolumab demonstrated durable responses, long-term survival, and manageable 
safety in patients with advanced HCC, regardless of viral aetiology and with or without prior 
sorafenib treatment.5 However, in the phase III CheckMate 459 study of nivolumab vs. 
sorafenib as first-line treatment in patients with advanced HCC, nivolumab did not reach 
statistical significance for OS vs. sorafenib, despite suggested clinical benefit with improved 
objective response rate (ORR) in nivolumab-treated patients.6 Therefore, it remains critical 
to understand the determinants behind responses to nivolumab and other ICIs.
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As evidence suggests, assessing candidate biomarkers of inflammation in clinical trials 
could increase understanding of the underlying immunobiology of advanced HCC, link 
patient clinical outcomes to ICI mechanisms of action (MOA), help predict response, and 
guide patient selection for ICI treatment.
Programmed death-ligand 1 (PD-L1), a ligand for the immune checkpoint receptor 
programmed death-1 (PD-1), is expressed on various cells, including tumour and immune 
cells. In some tumour types, such as non-small-cell lung cancer, PD-L1 expression has been 
associated with improved response.7,8 However, ICIs have demonstrated efficacy in other 
tumour types regardless of PD-L1 expression.9 Despite results from CheckMate 040 
reporting that objective responses occurred irrespective of PD-L1 expression, any potential 
association between PD-L1 expression and efficacy remains unclear.5
In addition, expression of CD4, CD8, PD-L1, PD-1, and FOXP3 has been used to identify 
populations of immune cells that correlate with response to sorafenib in patients with HCC.
10 A prior study involving sorafenib-treated patients with HCC showed that survival was 
associated with a reduction in CD4+ and CD8+ PD-1+ T cells. Additionally, a statistically 
significant improvement in OS was shown in patients exhibiting a greater decrease in the 
number of FOXP3+ regulatory T cells.10 These data suggest the importance of specific T 
cells in the pathobiology of HCC, as well as their potential utility as biomarkers of response.
Tumour-associated macrophages (TAMs) also play important roles in HCC pathobiology by 
suppressing antitumour immune responses and by promoting tumour growth, angiogenesis, 
and metastasis.11 In vitro evidence suggests that treatment with sorafenib induces 
recruitment and intratumour infiltration of macrophages.12 This leads to downstream 
elevations in various tumour and peripheral growth factors, suggesting the role of 
macrophages in tumour progression under sorafenib treatment.12 Similar results from Dong 
et al. suggest that CD68+/CD163+ M2 macrophages may contribute to sorafenib resistance 
in patients with HCC.13
Gene expression profiling (GEP) allows simultaneous assessment of various inflammatory 
markers, using next-generation sequencing–based techniques such as RNA sequencing 
(RNA-seq) to reveal gene clusters that represent a coordinated pattern of expression (gene 
expression signatures).14 Immune-related gene expression signatures have been previously 
studied in HCC. Sia et al. sought to isolate genomic signals using GEP in HCC tumours. 
Using these data, they identified a subgroup, referred to as an ‘immune class’, that showed 
significant enrichment of signatures identifying various immune cells. This immune class 
was shown to comprise 2 distinct microenvironment-based clusters with either an active or 
exhausted response, which may help determine which tumours will be responsive to ICIs.15 
These studies demonstrate the ability of GEP to provide a more ‘holistic’ or functional 
picture of the inflamed tumour microenvironment (TME).
Additionally, multiple prognostic markers have been investigated in HCC, including 
increased neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and 
alpha-fetoprotein (AFP).16-18 High serum AFP levels are strongly associated with poor 
prognosis in patients with advanced HCC,17 while patients with serum AFP levels >400 
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μg/L after first-line therapy with sorafenib showed an improved OS with ramucirumab vs. 
placebo.3
Thus, a more extensive assessment of tumour-infiltrating T cells, TAMs, gene expression 
signatures, and inflammation biomarkers would be informative for patients with advanced 
HCC. In the current study, several exploratory analyses were performed, investigating 
multiple biomarkers within the TME for potential associations with nivolumab efficacy in 
advanced HCC.
Materials and methods
Study design and endpoints
Study design details from CheckMate 040 have previously been published.5 Data presented 
here are from sorafenib-naive patients and patients with prior exposure to sorafenib cohorts 
in the dose-escalation and dose-expansion phases of CheckMate 040 (Fig. S1). The study 
included safety and tolerability, ORR (as assessed by Response Evaluation Criteria in Solid 
Tumors [RECIST] v1.1 via investigator and blinded independent central review [BICR] 
assessment), and OS as primary and secondary endpoints in the dose-escalation and dose-
expansion phases. Analyses were done in the overall population as well as in sorafenib-
experienced patients; the sorafenib-naive cohort was too small to be analysed separately. 
Best overall response (BOR) was evaluated as complete response (CR), partial response 
(PR), stable disease (SD), progressive disease (PD), or not evaluable (NE), according to 
RECIST v1.1. Exploratory analyses included various biomarkers that were assessed for their 
association with clinical outcomes including BOR and OS, the results of which are 
presented in this report.
Patient samples
Pretreatment tumour samples, including both fresh and archival biopsies and resections, 
were obtained from patients in the dose-escalation and dose-expansion phases receiving 
nivolumab 3 mg/kg or nivolumab 0.1–10 mg/kg. Pretreatment and on-treatment blood 
samples were collected from all patients to measure AFP, NLR, and PLR, and from virally 
infected patients to measure HBV surface antigen, HBV DNA, and HCV RNA.
Biomarker assessments
Biomarkers were investigated using baseline formalin-fixed, paraffin-embedded (FFPE) 
tumour samples and included the following: PD-L1 and PD-1 expression (measured by 
immunohistochemistry [IHC] in patients receiving nivolumab 3 mg/kg only), the presence of 
inflammatory cells in the TME (measured by IHC using markers of T-cell subsets and 
differentiated macrophages), measures of systemic inflammation (NLR, PLR, and AFP), and 
inflammatory gene expression signatures measured by RNA-seq (using tumour samples 
from patients across all dose cohorts). Tumour-cell PD-L1 expression was measured using 
the PD-L1 IHC 28-8 pharmDx assay (Agilent Technologies, Santa Clara, CA) and reported 
as the percentage of tumour cells with PD-L1 cell membrane staining at any level (% TC). 
CD3, CD4, CD8, FOXP3, PD-1, CD68, and CD163 IHC were performed by Mosaic 
Laboratories (Lake Forest, CA).
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GEP was performed using RNA-seq to analyse several gene signatures (Table 1), including 
an inflammatory gene expression signature consisting of 4 genes based on prior literature: 
CD274 (PD-L1), CD8A, LAG3, and STAT1.14,19
Serologic testing was completed centrally, while AFP was measured in blood samples 
locally using a standard laboratory test. Patients from dose-escalation and dose-expansion 
phases were stratified by baseline AFP levels to ≥400 μg/L or <400 μg/L. Patients with 
missing baseline AFP were excluded from this analysis. Neutrophils, lymphocytes, and 
platelets were measured locally using a complete blood count with differential and platelet 
counts.
HBV DNA viral load and HCV RNA viral load were both quantified by PCR in blood 
samples. Potential associations of the viral load of HCV (measured by HCV RNA) and HBV 
(estimated by HBV DNA or HBV surface antigen) with response to nivolumab were 
assessed in dose-escalation and dose-expansion cohorts. Measurements of viral load were 
assessed during patient therapy only and not during follow-up visits.
Biomarkers were assessed for their association with clinical outcomes including BOR by 
BICR per RECIST v1.120 and OS. The association of gene expression signatures and 
response to treatment (as assessed by ORR) was investigated.
Statistical analyses
Analyses were performed using the standard limma21 and Cox regression framework.22,23 
The models were adjusted for age and gender across all analyses. Additional covariates, 
such as race and viral aetiology, were used when analysing associations between gene 
signatures and BOR or OS. Descriptive p values at a 2-sided significance level of 0.05 were 
reported. No multiplicity control of type I error of these comparisons was applied.
Results
Biomarker-evaluable patients
The cut-off date for this analysis was May 2018 with a median follow-up time of 33.2 
months. In this exploratory biomarker analysis of CheckMate 040, 195 samples from 
patients from the dose-escalation and dose-expansion phases receiving 3 mg/kg nivolumab 
were evaluable for PD-L1 expression, and analyses were performed on other biomarkers 
based on sample availability. Inflammatory gene signatures were analysed by RNA-seq in 
GEP-evaluable pretreatment samples (n = 37) from patients receiving any dose of nivolumab 
(0.1–10 mg/kg). All other biomarkers were assessed in patient samples from the dose-
escalation or dose-expansion phases receiving 3 mg/kg nivolumab. The numbers of patients 
evaluated for each biomarker are listed in Fig. S1. Of the 195 PD-L1–evaluable patients, 58 
were sorafenib-naive and 137 were sorafenib-experienced (Table 2). The baseline 
characteristics of the overall trial population and the GEP-evaluable cohort are included in 
Table S1.
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BOR by PD-L1 and PD-1 status
BOR (assessed by BICR per RECIST v1.1) was correlated with tumour PD-L1 status (Table 
2). Clinically meaningful responses were observed in the overall population as well as in 
sorafenib-experienced patients, including patients with PD-L1 <1% (6 CR and 19 PR). In 
the overall population and in the sorafenib-experienced group, numerically higher ORRs 
were observed in patients with PD-L1 ≥1% vs. PD-L1 <1% (Table 2). The sorafenib-
experienced population had ORRs comparable to those of the overall population.
Best reductions from baseline in target lesions were comparable in the overall population 
and sorafenib-experienced group; reductions were observed regardless of PD-L1 status (Fig. 
1).
Association of PD-1 expression with BOR was also investigated. PD-1 expression was 
associated with BOR, with a median PD-1 expression of 1.675% (IQR 0.595–4.378). 
Percentage of PD-1+ cells trended higher in patients with CR/PR (n = 34) vs. patients with 
SD (n = 71) (p = 0.05) and patients with PD (n = 73) (p = 0.009) (Fig. 2C).
OS by PD-L1 and PD-1 status
In the overall population, tumour PD-L1 expression ≥1% was associated with improved OS 
(p = 0.032) (Fig. 2A). Median OS was 28.1 months (95% CI 18.2–n.a.) for patients with PD-
L1 ≥1% vs. 16.6 months (95% CI 14.2–20.2) for patients with PD-L1 <1% (Fig. 2A).
Although sorafenib-experienced patients with PD-L1 ≥1% experienced numerically greater 
OS, the difference between patients with PD-L1 <1% and ≥1% was not statistically 
significant (p = 0.12) (Fig. 2B).
In an analysis of OS by PD-1 expression level, higher levels of PD-1 trended toward 
increased OS (p = 0.05, based on analysis of PD-1 expression as a continuous variable) (Fig. 
2D).
Markers of inflammatory cell infiltration and association with BOR or OS
There was increased frequency of CD3+ T cells in patients at baseline compared with other 
T-cell markers assessed (Fig. 3A). IHC assessment of tumour-infiltrating T cells expressing 
CD3 (median, 7.97% [IQR, 3.42–16.64]) or CD8 (3.04% [IQR, 1.45–7.18]), but not CD4 
(1.72% [IQR, 0.57–5.71]) or FOXP3 (0.55% [IQR, 0.23–1.22]), showed a trend towards 
improved OS (both p = 0.08) (Fig. 3B-E).
An increased frequency of CD3+ T cells was associated with BOR of CR/PR compared with 
SD (p = 0.03). The association between increased frequency of CD3+ T cells in patients with 
CR/PR compared with PD did not reach statistical significance (Fig. S2A). Other markers 
for T-cell subsets (CD4, CD8, and FOXP3) were not correlated with BOR (Fig. S2B-D).
Phenotypic markers for polarised macrophages were analysed by IHC to explore potential 
associations with clinical response. The median expression of CD68+ and CD163+ cells was 
14.39% and 3.2%, respectively (Fig. S3). As shown in Fig. 4A-D, there was no association 
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between higher frequencies of macrophage infiltration, measured by CD68+ or CD163+ 
staining, and either BOR or OS.
Associations between inflammatory gene signatures and clinical benefit
Associations with efficacy to nivolumab were analysed for 10 different gene expression 
signatures measured at baseline in a subgroup of 37 patients. These assessments included a 
post hoc analysis for associations with efficacy using gene signatures belonging to the 
‘immune class’ previously described by Sia et al.15 (Table 1). A full list of these genes can 
be found in Table S2. Baseline characteristics of this subgroup compared with the overall 
treated population are described in Table S1. Associations with either ORR or OS were 
observed for 7 of the 10 evaluated gene expression signatures, while associations with both 
ORR and OS were observed for the inflammatory signature consisting of 4 genes, the 13-
gene inflammatory signature, the 6-gene interferon gamma signature, and the T-cell 
exhaustion signature (Table 1). In particular, the inflammatory signature consisting of 4 
genes was associated with an improved response (CR/PR) and OS (p = 0.01) to nivolumab 
therapy in the CheckMate 040 dose-escalation and dose-expansion phases (Table 1). 
Alternatively, the signature included in the post hoc analysis15 showed no associations with 
response (p = 0.15) or survival (p = 0.29) (Table 1).
Higher median inflammatory signature scores trended toward an association with PR vs. SD 
(p = 0.05). The association between increased inflammatory signature score in patients with 
PR compared with PD did not reach statistical significance (Fig. 5A) (associations between 
signature scores and patients with a CR could not be made, as GEP data were not available 
for these patients). Patients with inflammatory gene expression signature scores in the upper 
tertile showed improved OS in response to nivolumab, compared with patients with low or 
medium scores (p = 0.01) (Fig. 5B).
Markers of systemic inflammation and association with BOR or OS
At baseline in the overall patient group, median NLR was 2.87 (IQR, 2.0–3.95). Patients 
with PD (n = 102) trended toward a higher median NLR vs. patients showing CR or PR (n = 
43; p = 0.31). A trend toward higher median NLR was also demonstrated for patients with 
PD (p = 0.11) vs. patients with SD (n = 98). OS was longer in patients with NLR in the 
lower tertile compared with patients with NLR in the medium or high NLR tertiles (p = 
0.015) (Fig. 6A).
At baseline in the overall patient group, median PLR was 149 (IQR, 97.67–199.23). PLR 
was lower in patients with CR or PR compared with PD (p = 0.05) (Fig. 6B), and analysis of 
PLR levels by tertiles demonstrated improved OS in response to nivolumab treatment in 
patients with low PLR compared with medium or high PLR (p = 1.38e-07) (Fig. 6C).
AFP and association with BOR or OS
Patients with baseline AFP <400 μg/L (n = 92) demonstrated numerically improved median 
OS of 16.8 months (95% CI 13.3–20.2) compared with a median OS of 13.0 months (95% 
CI 8.0–17.5) in patients with AFP ≥400 μg/L (n = 57). In addition, while there were slight 
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differences in the 24-month OS rate, the ORR and disease control rate (DCR) were similar 
regardless of baseline AFP (Fig. S4).
Viral load measured during nivolumab treatment and association with response
A suppression of viral replication in patients with HCV infection (indicated by a >1 log-
change decline in HCV RNA from baseline) was observed with nivolumab treatment in 
some patients, but there was no association with tumour response (Fig. S5). Viral 
breakthrough (defined as a 1 log10 increase over baseline in HBV DNA or HCV RNA, or 
HBV DNA >200 IU/mL) was rarely observed with nivolumab treatment in HBV- or HCV-
infected patients. Increased HBV replication (measured by increased HBV DNA or 
increased HBV surface antigen) did not associate with clinical deterioration or tumour 
response (Fig. S6). Seven percent (3/42) of HBV-infected patients treated with nivolumab 
demonstrated a >1 log decrease in HBV surface antigen (Fig. S7).
Discussion
This exploratory analysis of CheckMate 040 identified multiple inflammation biomarkers 
that associate with improved response and survival to nivolumab in patients with advanced 
HCC. These biomarkers may be indicative of a T-cell–inflamed TME or systemic 
inflammation. In addition to an increased understanding of inflammatory disease 
mechanisms in HCC, these results provide insights into how such biomarkers, either alone or 
in combination, may act as potential predictors of response to nivolumab therapy.
However, these exploratory analyses have several limitations. There were small numbers of 
biomarker-evaluable samples obtained for this study. For the sorafenib-experienced patients, 
a mixture of fresh and archival tumour samples was collected. The use of archival tissue in 
some patients may not account for changes in the TME occurring between tumour collection 
and nivolumab treatment and caused by the natural progression of the disease over time or 
an intervening therapy such as sorafenib. The absence of a multivariate analysis means 
potential confounders, such as baseline liver function, were not captured, which could 
impact survival outcomes. Finally, additional inclusion of 9 patients from the dose-escalation 
cohort could have impacted results.
PD-L1 expression (on ≥1% of tumour cells) was associated with improved OS in the overall 
patient population (sorafenib-naive and sorafenib-experienced). Separate analysis of the 
sorafenib-naive population was not carried out due to small sample size; however, this will 
be completed in a study with a larger population. ORRs were higher in the PD-L1 ≥1% 
subgroup compared with the PD-L1 <1% subgroup, but CR and PR also occurred in patients 
with PD-L1 levels <1%. Additionally, significant changes in target lesion size occurred 
regardless of PD-L1 expression. Therefore, PD-L1 expression alone may not serve as an 
adequate biomarker.
Tumour-infiltrating T cells often show evidence of exhaustion, including upregulation of 
PD-1 and other inhibitors of immune function.24 In this study, high PD-1 expression was 
associated with a CR or PR to nivolumab and a trend toward improved OS. These results are 
consistent with other trials evaluating the efficacy and safety of PD-1 inhibitors.25 High 
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PD-1 expression may be indicative of exhausted T cells in the TME and may identify 
patients who would derive benefit from ICI therapy via inhibition of the PD-1/PD-L1 
signalling axis.
In a study that characterised HCC tumour-infiltrating inflammatory cells, the number of 
CD8+ T cells in the tumour core was lower than those in the outer cortex, which may 
suggest inefficient tumour infiltration. However, GEP revealed gene signatures indicative of 
exhausted CD8+ T cells, whereas IHC and flow cytometry showed an enrichment of 
regulatory T cells in the HCC TME.26 Consistent with these data, our analysis showed that 
higher CD3+ T-cell frequency measured in tumour samples by IHC was associated with CR 
or PR to nivolumab, with a trend towards improved OS with increased CD3+ and CD8+ 
cells. Consistent with previous GEP data suggesting the importance of T-cell exhaustion and 
tumour T-cell infiltration in HCC, GEP presented in this study indicated that exhausted 
CD3+ T cells were associated with response to nivolumab. Conversely, the frequency of 
FOXP3+ regulatory T cells, measured by IHC, did not appear to correlate significantly with 
response to nivolumab in the current analysis.
Alternatively, activated (M2) macrophages measured by IHC with anti-CD163 contribute to 
poor prognosis in HCC.27 The current analysis found no association between higher 
frequencies of either M1 or M2 macrophage infiltration, measured by CD68+ (all 
macrophages) or CD163+ staining (M2 macrophages), and either BOR or OS. The increased 
frequency of CD68+ macrophages relative to CD163+ is likely the consequence of CD68 
expression on all macrophages.
Associations between inflammatory gene expression signatures and ORR and OS in patients 
from CheckMate 040 are consistent with previous studies showing positive associations 
between inflammatory gene signatures and enhanced clinical benefit from ICI therapy in a 
range of tumour types, including melanoma, squamous cell carcinoma of the head and neck, 
and gastroesophageal cancer.28-30 Inflammatory gene expression signatures, including the 
inflammatory signature consisting of 4 genes discussed in this study, have also been 
associated with response to nivolumab with or without ipilimumab in patients with 
metastatic gastroesophageal cancer.30 Expression of the 4 genes in the inflammatory 
signature may be revealing interferon-gamma/STAT1-dependent CD8+ T-cell expansion, 
LAG-3–dependent T-cell exhaustion, and/or an immune-suppressed TME with high PD-L1 
expression. Thus, this signature may be indicative of those patients who would be most 
responsive to inhibition of PD-L1/PD-1 signalling by nivolumab. While both the main and 
post hoc analyses included several relevant gene signatures concerning the inflammatory 
nature of the TME, they did not encompass all gene signatures that may be associated with 
clinical outcomes in patients with HCC. Taken together, results from multiple assessments 
of the TME in patients with advanced HCC suggest a connection between T-cell 
inflammation, the MOA of nivolumab, and clinical outcomes associated with nivolumab. 
The association of other biomarkers with response to immuno-oncology therapy may reveal 
complex mechanisms of immune escape, via engagement of CTLA-4, PD-L1, or alternative 
mechanisms of immune suppression.
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Markers of systemic inflammation, such as elevated NLR, PLR, and AFP, are associated 
with poor prognosis in HCC.18,31 Lower NLR was predictive of a greater OS benefit in 
patients with advanced HCC upon treatment with sorafenib, an oral multikinase inhibitor.31 
In this analysis, lower NLR and lower PLR were associated with CR or PR to nivolumab, 
and low AFP showed a numerical (although not statistically significant) association with 
response.
In this study, patients treated with nivolumab demonstrated durable responses and improved 
long-term survival regardless of viral aetiology. These observations suggest that viral load or 
antiviral immune responses to HBV/HCV may not have an impact on the T-cell–stimulating 
antitumour mechanisms of nivolumab. The increase in viral replication observed in some of 
the patients with HCV or HBV was not clinically relevant.
Assessment of inflammation biomarkers could increase our understanding of the MOA of 
nivolumab and how they relate to clinical response. Importantly, our results are consistent 
with the MOA of PD-1 inhibition with regard to the importance of PD-L1 expression and 
pre-existing immunity in the TME. Our data support both the importance of this MOA in 
this tumour type and the use of nivolumab as indicated for patients with HCC.
Future biomarker studies may increase understanding of the key molecular drivers of 
antitumour immunity and continue to support the connection between the MOA of 
nivolumab and efficacy in HCC. Combinatorial assessment of multiple inflammation 
biomarkers, including those studied in this report, may help further dissect the complexities 
of the inflamed TME in HCC. Finally, larger controlled studies in HCC could also help 
evaluate the potential predictive/prognostic values of inflammatory biomarkers for 
nivolumab treatment response.
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BICR blinded independent central review
BOR best overall response
CR complete response
DCR disease control rate
FFPE formalin-fixed, paraffin-embedded
GEP gene expression profiling
ICI immune checkpoint inhibitor
IHC immunohistochemistry
MOA mechanism of action
NE not evaluable
NLR neutrophil-to-lymphocyte ratio
ORR objective response rate
OS overall survival
PCR polymerase chain reaction
PD progressive disease
PD-1 programmed death-1
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• Many inflammation-related markers are associated with response to 
nivolumab in HCC.
• Many inflammatory signature scores within tumour samples are associated 
with survival.
• Lower ratios of systemic inflammation markers are associated with clinical 
benefit.
• Patients with HCC demonstrated positive responses regardless of AFP and 
viral dynamics.
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Fig. 1. Best change in target lesion by tumour programmed death-ligand 1 (PD-L1).
Sangro et al. Page 16













Fig. 2. Association of PD-L1 and PD-1 expression with OS and BOR.
†This is an exploratory analysis with a small sample size of biomarker-evaluable patients in 
the overall population (SOR-naive and SOR-experienced). *p values calculated through a 
continuous model based on data available. Tertiles are for visualisation purposes. Whiskers 
represent values 1.5× the upper and lower limits of the IQR (A) OS by PD-L1 (overall 
population). (B) OS by PD-L1 (SOR-experienced). (C) PD-1 (overall population) by BOR. 
aUsing RECIST v1.1. (D) OS by PD-1 (overall population). BOR, best overall response; CR 
complete response; IQR, interquartile range; OS, overall survival; PD-1, programmed 
death-1; PD-L1, programmed death-ligand 1; PR, partial response; SD, stable disease; SOR, 
sorafenib.
Sangro et al. Page 17













Fig. 3. Distribution of T-cell markers and OS by T-cell markers.
†This is an exploratory analysis with a small sample size of biomarker-evaluable patients in 
the overall population (SOR-naive and SOR-experienced). *p values calculated through a 
continuous model based on data available. Tertiles are for visualisation purposes and are 
based on T-cell marker frequency. (A) Distribution of T-cell markers in the overall 
population. (B) OS by CD3 (overall population). (C) OS by CD4 (overall population). (D) 
OS by CD8 (overall population). (E) OS by FOXP3 (overall population). OS, overall 
survival.
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Fig. 4. BOR and OS by macrophage marker status.
aUsing RECIST v1.1; macrophage markers measured as a percentage of all nucleated cells. 
†This is an exploratory analysis with a small sample size of biomarker-evaluable patients in 
the overall population (SOR-naive and SOR-experienced). *p values calculated through a 
continuous model based on data available. Tertiles are for visualisation purposes and are 
based on macrophage marker frequency. (A) CD68+ by BOR. (B) OS by CD68+. (C) 
CD163+ by BOR. (D) OS by CD163+. BOR, best overall response; CR, complete response; 
OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease; SOR, 
sorafenib.
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Fig. 5. Inflammatory signature score in tumour samples and clinical response.
aUsing RECIST v1.1. †This is an exploratory analysis with a small sample size of 
biomarker-evaluable patients in the overall population (SOR-naive and SOR-experienced). 
*p values calculated through a continuous model based on data available. Tertiles are for 
visualisation purposes and are based on inflammatory signature score. (A) Inflammatory 
signature score by BOR. (B) OS by inflammatory signature score tertiles. BOR, best overall 
response; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable 
disease; SOR, sorafenib.
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Fig. 6. NLR and PLR association with clinical response.
aUsing RECIST v1.1. †This is an exploratory analysis with a small sample size of 
biomarker-evaluable patients in the overall population (SOR-naive and SOR-experienced). 
*p values calculated through a continuous model based on data available. Tertiles are for 
visualisation purposes and are based on NLR and PLR values. (A) OS by NLR. (B) PLR by 
BOR. (C) OS by PLR. BOR, best overall response; CR complete response; NLR, neutrophil-
to-lymphocyte ratio; OS, overall survival; PLR, platelet-to-lymphocyte ratio; PR partial 
response; SD, stable disease.
Sangro et al. Page 21





















































































































































































































































































































































































































































































































































































































































































































































































































Sangro et al. Page 23
Table 2.
Best overall response by tumour PD-L1 status.







 Total, n (%) 159 (82) 110 (80)
 Objective response rate, % (95% CI) 16 (11–22) 13 (8–20)
 Complete response, n (%) 6 (4) 4 (4)
 Partial response, n (%) 19 (12) 10 (9)
 Stable disease, n (%) 66 (42) 49 (45)
 Progressive disease, n (%) 59 (37) 42 (38)
PD-L1 ≥1%
 Total, n (%) 36 (18) 27 (20)
 Objective response rate, % (95% CI) 28 (16–44) 26 (13–45)
 Complete response, n (%) 2 (6) 1 (4)
 Partial response, n (%) 8 (22) 6 (22)
 Stable disease, n (%) 9 (25) 8 (30)
 Progressive disease, n (%) 15 (42) 10 (37)
PD-L1, programmed death-ligand 1; SOR, sorafenib.
Responses not determined in overall population: 9 patients with PD-L1 <1% and 2 patients with PD-L1 ≥1%; sorafenib-experienced population: 5 
patients with PD-L1 <1% and 2 patients with PD-L1 ≥1%.
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